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Edited by Robert BaroukiAbstract We present here a combined GC–MS and LC–MS
metabolic proﬁling approach to unraveling the pathological out-
comes of aristolochic acid (AA)-induced nephrotoxicity. Urine
samples were analyzed by GC–MS and LC–MS in combination
with pattern recognition techniques, e.g. principal component
analysis (PCA), orthogonal projection to latent structure-dis-
criminant analysis. The work indicates that AA-induced acute
renal toxicity as evidenced by histopathological examinations
could be characterized by systemic disturbance of metabolic net-
work involving free fatty acids generation, energy and amino
acids metabolism, and alteration in the structure of gut microbi-
ota. Therefore, this method is potentially applicable to the toxi-
cological study, providing a comprehensive understanding of
systems response to xenobiotic intervention.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Aristolochic acid (AA), widely present in the botanicals,
i.e. Aristolochia, Bragantia and Asarum species, is generally
believed to cause acute renal failure (ARF), characterized by
interstitial ﬁbrosis, hyperproteinemia, severe anaemia, and ure-
mia [1–4]. Conventional toxicological studies on AA focused
merely on nephrotoxic mechanisms such as the activation or
inhibition of certain enzymes related to the renal lesion [5–9].
Recently, the revival of systems biology aiming to integrate
all the pertinent components, e.g. genes, proteins, and metab-Abbreviations:MS, mass spectrometry; GC–MS, gas chromatography–
mass spectrometry; LC–MS, liquid chromatography–mass spectro-
metry; NMR, 1H nuclear magnetic resonance; CE-MS, capillary
electrophoresis-mass spectrometry; PCA, principal component analy-
sis; OPLSDA, orthogonal projection to latent structure-discriminant
analysis
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network provides comprehensive thoughts in understanding
and addressing systems’ behavior [10,11].
Metabolomics/metabonomics, concomitant with genomics,
metagenomics, proteomics, etc., is a newly thriving systems
biology and has been highly favored in botanical science
[12], environmental research [13], and toxicological study in
preclinical and clinical ﬁelds [14–17]. The goal of global meta-
bolic proﬁling is to monitor as many metabolites with low
molecular weight as possible in a single cell, bioﬂuids, and tis-
sue extracts [18]. However, none of the analytical instruments
including NMR, GC–MS, LC–MS, and CE-MS has so far
been able to capture the entire composition of endogenous
metabolites. The use of multiple analytical methods in combi-
nation may oﬀer a better strategy for identifying a broadened
spectrum of important metabolites associated with physiologi-
cal and/or pathological variations [19–21].
It is technically challenging to integrate data from diﬀerent
analytical methods which measure diﬀerent types of biochemi-
cal molecules generated from diverse aspects of a system,
during which repercussions resulting from systematic biases,
false-positive or -negative rates inherent in the high-through-
put assays are to be under scrutiny [10,22]. To date, enormous
eﬀorts have been made to integrate a variety of data from mul-
tiple analytical platforms, which have facilitated the identiﬁca-
tion of subtle variation between two physiological states using
simpliﬁed mathematical models [11,22,23].
We have previously established a time-dependent changing
metabonomic proﬁle in AA-induced nephrotoxic model using
HPLC-ESI-MS [24]. In this work, we repeated the previous
study using GC–MS analytical technique, in which we have
identiﬁed a number of important metabolites related to AA
toxicity. Multivariate statistical analysis was used to process
the integrated dataset generated from LC–MS and GC–MS,
allowing a comprehensive understanding of mechanisms of
AA-induced nephrotoxicity.2. Materials and methods
2.1. Animal handling and sampling
The study was approved by China national legislation and local
guidelines. The experimental protocols followed our previously pub-
lished work [24]. Urine samples were collected at diﬀerent time-points
from the male Wistar rats dosed with AA or vehicle, and immediately
kept at 70 C until MS measurement.blished by Elsevier B.V. All rights reserved.
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Each 300-lL aliquot of urine sample was mixed with 300 lL of
water for ethyl chloroformate (ECF)-derivatization prior to GC–MS
spectral acquisition as described[25]. One microlitre of the analyte
was injected into a DB-5MS capillary column coated with 5% diphenyl
cross-linked 95% dimethylpolysiloxane (30 m · 250 lm i.d., 0.25 lm
ﬁlm thickness; Agilent J&W Scientiﬁc, Folsom, CA) performed on a
hyphenated analytical technique, gas chromatography–mass spectro-
metry (Perkin–Elmer Inc., USA).2.3. LC–MS spectroscopy acquisition
Details of the protocol were provided in our previously published
paper [24].
2.4. Preprocessing of data
The data from the GC–MS and LC–MS analysis were converted to
NetCDF format via DataBridge (Perkin–Elmer Inc.) and Agilent LC/
MSD ChemStation (Rev.B.01.03, Agilent Tech., USA), respectively.
Each ﬁle was extracted subsequently using our custom scripts in the
MATLAB 7.0 (The MathWorks, Inc., USA), where baseline correc-
tion, and peak resolving and alignment were carried out. The output
data were organized in the form of arbitrary peak index (retention
time–m/z pair), sample names (observations), and peak intensity infor-
mation (variables).
Directly concatenating the matrices of processed-MS data is sub-
optimal as this may result in a matrix with an unfavorable samples-
to-variables ratio [22]. It is necessary to use properly reduced matrix
to conduct multivariate statistical analysis. Notably, GC–MS data
inherently contain apparent variability and complexity such as multi-
ple fragments from a single compound. A simple strategy was to com-
bine these fragments with the same retention time into a single
compound. The binning procedure should be manually conﬁrmed by
comparing the major ion fragments of a compound detected with those
from commercially available and in-house libraries in order to mini-
mize the prejudice to confounding peaks. Using previously established
GC–MS analysis protocol, we detected about 200–250 diﬀerent urine
metabolites, with 87 of them identiﬁed by means of the library or ver-
iﬁed via authentic standards. Lacking the eﬀective peak resolving
method for LC–MS data, we used an optimized voltage, which is kept
stable and constant throughout the experiment, to obtain a number of
the corresponding molecular ions [M+H+] deriving from endogenous
metabolites. Ultimately, an integrated matrix was obtained for subse-
quent multivariate statistical analysis by merging the two sets of
data.
Since MS-data were obtained from diﬀerent analytical instruments
and urine volume varied over subjects, block normalization to the total
sum of the chromatogram was conducted on GC–MS and LC–MS
data, respectively. The internal standard for on-line supervising in-
ter-batch reproducibility and for automated peak matching algorithm
of retention time was removed prior to the normalization. Mean-cen-
tering was performed columnwise to remove the oﬀsets and autoscal-
ing (scaled to unit variance) to put all the measured metabolites on
an equal level. That is, metabolites present at low concentrations are
of equal importance with those present at high concentrations.Fig. 1. PCA scores plot (PCI versus PC2) derived from the integrated
MS data of urine samples obtained from AA-induced nephrotoxicity
rats (.) and the healthy control (m). Hotelling T2 ellipse = 95%
conﬁdence limit.2.5. Multivariate statistical analysis
GC–MS and LC–MS data of urine samples from the two groups
(AA-induced nephrotoxicity group versus the healthy control) at the
7th day postdose were analyzed by principal component analysis
(PCA) to envisage the perturbation of the metabolic network of the
AA-treated animals. Orthogonal projection to latent structure-discrim-
inant analysis (OPLSDA) was carried out on the integrated MS data
allowing the identiﬁcation of diﬀerential metabolites in the urine. In
the OPLSDA algorithm, the variation in X (the combined MS data)
is decomposed into three parts: the ﬁrst being the variation in X related
to Y (the class variable, e.g., 0/1), and the last two containing the spe-
ciﬁc systemic variation in X and residual, respectively. This leads to a
model with a minimal number of predictive components deﬁned by the
number of degrees of freedom (k  1 dimensions) between group
variances (k classes). Therefore, the interpretation of diﬀerential
metabolites in the two groups is straightforward using one loading
alone. To validate the model against over-ﬁtting, the prediction accu-
racy (cross-validation parameter) Q2
bY
was computed. Details regarding
OPLSDA algorithm are available in other publications [26].3. Results
3.1. PCA of integrated MS matrix
The scores plot (PC1 versus PC2) derived from the inte-
grated MS-data (Fig. 1) depicted two distinct clustering with-
out any overlap between the groups (AA-treated group and
the healthy control). The separation of the two groups oc-
curred in the PC1, and the cluster appeared to be tighter in
the healthy control group as compared to the AA-dosed
group. These ﬁndings were in good agreement with LC–MS-
based metabolic proﬁles as well as the histopathological exam-
ination [24].
3.2. Investigation of the diﬀerential metabolites by OPLSDA
OPLSDA model was generated with one predictive compo-
nent, and one orthogonal component to discriminate the two
group rats. R2X and R2Y represented the fraction of the vari-
ation of all the X variables (the combined MS data) and the
‘‘dummy’’ Y variables (0/1) by the model, respectively. The
R2Y values in this work (approximately 1.0) suggested a satis-
factory model (Fig. 2a). The prediction accuracy (Q2Y > 0.75)
obtained through a typical 7-fold cross-validation further
guaranteed the models (Fig. 2a). Additionally, the distance
to model is calculated for each sample using the integrated
MS data (a critical value of 99.5% for outliers marked as a
dashed line) in case of spurious eﬀects of outlying samples
(Fig. 2b). However, no outlying data point was observed at
this threshold, meaning that any metabolite of interest mir-
rored the general eﬀects after exposure to AA. The correlation
coeﬃcients (r > 0.70 was considered as having good discrimi-
nant ability) resulting from OPLSDA of the integrated MS
data were summarized in Table 1, where the metabolites were
designated according to the corresponding GC–MS and LC–
MS analyses. The reduced urinary excretion levels of citrate,
aconinate, isocitrate, succinate, m-hydroxyphenylpropionate,
caprylic acid, valeric acid, arachidonic acid, methionine, and
elevated levels of serine, p-cresol, p-hydroxyphenylacetate, cys-
tine, cysteine, and homocysteine were detected in the AA-
dosed rats as compared to the healthy controls. These metab-
olites were identiﬁed by authentic standards available (Sigma–
Aldrich, USA) and the commercial compound libraries: NIST,
Wiley in Turbomass 4.1.1 software (Perkin–Elmer Inc.). No
overlap in analytical outcomes was observed between the
Fig. 2. (a) OPLSDA model summary of the combined MS dataset.
For more explanation of the R2X, R2Y, and Q2Y values, see the text.
(b) The distance to model plot. (d, sample values).
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MS and LC–MS techniques.4. Discussion
In this study, we have veriﬁed the previous research results
using a diﬀerent analytical method. Based on the integrated
MS matrix, we have adopted OPLSDA to identify the per-
turbed metabolic pathways relating to AA-induced nephro-
toxicity. The work suggested that the application of diﬀerent
analytical methods may capture diﬀerent sets of endogenous
metabolites with unique biological signiﬁcance, and that inte-
gration of dataset from multi-analytical platforms is techni-
cally feasible and of great signiﬁcance for a comprehensive
understanding of systemic perturbation.Table 1
A list of most profound metabolites relevant to the AA-induced nephrotoxi
Metabolites (GC–MS) Correlation coeﬃcientsa
Citrate 0.83 (ﬂ)
Aconitate 0.76 (ﬂ)
Isocitrate 0.91 (ﬂ)
Succinate 0.79 (ﬂ)
m-Hydroxyphenylpropionate 0.74 (ﬂ)
p-Cresol 0.84 (›)
p-Hydroxyphenylacetate 0.79 (›)
Cystine 0.81 (›)
Cysteine 0.92 (›)
aThe correlation coeﬃcients shown are based on the OPLSDA of the integrat
the AA-dosed group (denoted by an up-arrow), whereas negative value reprMetabolic disorder of amino acids, homocysteine and serine
in particular, is commonly used as the criteria for diagnosis of
kidney morbidity [5–9]. In this study, such disturbed amino
acids as cystine, cysteine, homocysteine, methionine, and ser-
ine identiﬁed in the urine probably reﬂected the impaired renal
tubule and subsequent cellular interstitial ﬁbrosis due predom-
inately to the direct cytotoxic eﬀects of AA on kidney [27]. In
addition, the signiﬁcant variations of homocysteine and methi-
onine were detected by LC–MS analysis, whereas changes in
cystine and cysteine concentration were observed by GC–MS
analysis. Combining the results obtained from two analytical
methods together, a disturbed metabolic pathway emerged
(Fig. 3a) [28], beneﬁting from the use of two complementary
methods.
The negative OPLSDA correlation coeﬃcients of the fatty
acids such as caprylic acid, valeric acid and arachidonic acid,
indicated the declined levels of these metabolites in the AA-
dosed group as compared to the healthy control. Arachidonic
acid, an intermediate in the production of prostaglandins
(PGs), is produced during the process of phospholipids hydro-
lyzation by means of phospholipase A2 (PLA2) into lecithin
and phosphatidylinostitol. Phospholipase A2 (PLA2) is greatly
inhibited by AA, leading to a reduced level of arachidonic acid
(Fig. 3b) [28–32]. The down-regulated production of arachi-
donic acid may negatively impact the production of PGs which
play important roles in renal functions, e.g. attenuating renal
vasodilatation, regulating renal circulation, and aﬀecting renal
sodium excretion and water reabsorption, ultimately leading to
kidney lesion [33]. It is therefore assumed that depletion of ara-
chidonic acid may be one of the fundamental causes of acute
renal failure induced by AA.
GC–MS analytical method was able to identify the signiﬁ-
cant variations of phenyl-containing compounds such as p-cre-
sol, p-hydroxyphenylacetate, andm-hydroxyphenylpropionate.
These compounds are manipulated mainly by gut microbiota in
the living systems through fermentation of dietary polyphenols
and aromatic amino acids [34]. The variations in phenyl-con-
taining metabolites suggested that the gut microbiota was
greatly restructured by the AA intervention. The principal
metabolites of AA are aristolactam I, aristolactam Ia, and aris-
tolactam II that are produced through classical bacterial nitro-
reductase, and these aristolactams are the precursors of AA–
DNA adducts responsible for triggering or accelerating a ﬁbro-
tic process [35–38]. In this context, the signiﬁcant disorders of
symbiotic bacteria may be indicative of AA-induced acute kid-
ney lesion.
It has been well documented that citrate, aconite, iso-citrate
and succinate are the crucial substances of tricarboxylic acidscity
Metabolites (LC–MS) Correlation coeﬃcientsa
Caprylic acid 0.84 (ﬂ)
Valeric acid 0.92 (ﬂ)
Arachidonic acid 0.79 (ﬂ)
Methionine 0.81 (ﬂ)
Serine 0.92 (›)
Homocysteine 0.78 (›)
ed MS dataset, positive value indicates an increase of the metabolites in
esents a decreased level of the metabolites in this group.
Fig. 3. The perturbed metabolic pathways in response to AA exposure: (a) AA-induced metabolic disorder of amino acids; (b) AA perturbed TCA
cycle; (c) PLA2-related mechanisms of AA-induced nephrotoxicity. Dark square denotes an elevated concentration of metabolites present in the
urine from rats exposed to AA, whereas gray square means a reduced level of metabolites in this group as compared to the healthy.
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cose degradation and is primary energy supplier for universal
organisms. Following the nephrotoxicity induced by AA, these
compounds were signiﬁcantly decreased when compared with
the healthy control animals, suggesting that AA may inhibit
the activity of these compounds, ultimately repressing energy
metabolism [39,40]. This ﬁnding was consistent with the experi-
mental observations on AA-treated rats with much reduced
daily activity and a tendency to press close together.
The combined use of multiple analytical instruments, such as
GC–MS and LC–MS, takes advantage of complementary out-
comes and therefore, provides an improved analytical means
for explaining the biological variation in the living systems.
Our study using the combined MS-based metabolic proﬁling
technique has revealed that AA led to direct cytotoxic eﬀect
and enzyme inhibition, and to the signiﬁcant alteration of
gut-motivated metabolites and energy metabolism, ultimately
leading to a disruption of the kidney-related metabolic regula-
tory network and renal function.
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